June 6, 2023 12:06 PM EDTUpdated June 7, 11:12 AM
News Briefing

Ital­ian AAV biotech clos­es $65M Se­ries A; GSK's Jem­per­li nabs pri­or­i­ty re­view in en­dome­tri­al can­cer

Amber Tong

Paul Schloesser

Associate Editor

Tyler Patchen

News Reporter

AA­Vant­garde, a Mi­lan-based AAV biotech, has closed a €61 mil­lion ($65.1 mil­lion) Se­ries A round.

The biotech cur­rent­ly has two AAV plat­forms, one us­ing DNA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times